Point-of-care PSA testing: an evaluation of PSAwatch.

Authors :: Karim, O
Rao, A
Emberton, M
Cochrane, D
Partridge, M
Edwards, P
Walker, I
Davidson, I
Source :: Prostate Cancer & Prostatic Diseases; 2007, Vol. 10 Issue 3, p270-273, 4p, 2 Color Photographs, 1 Diagram, 1 Chart, 1 Graph
Publication Year :: 2007
Abstract: We present a new quantitative prostate-specific antigen (PSA) assay using a portable, point-of-care test (PSAwatch) and reader system (BioScan) for measuring PSA concentrations in the range from 0.5 to 25 μg/l. Blood samples from patients (n=199) were submitted for laboratory PSA and also evaluated using PSAwatch and the BioScan system. PSA concentrations in 188 men were 25 μg/l and studied. Correlation between the two methods was good (R<superscript>2</superscript>=0.88) with a standard error of 1.588. The regression line had a bias of −0.02 at the concentration of 4.00 μg/l. This is the first report of a quantitative, portable, point-of-care PSA test and reader system. PSAwatch may reduce the number of hospital visits for patients with prostate disease.Prostate Cancer and Prostatic Diseases (2007) 10, 270–273; doi:10.1038/sj.pcan.4500962; published online 13 March 2007 [ABSTRACT FROM AUTHOR]